FDA Anti-Infective Drugs Advisory Committee
Will meet July 22 to discuss efficacy supplement NDA (50- 605/S-017) for Glaxo's Ceftin (cefuroxime axetil) for treatment of early Lyme disease. On the morning of July 23, the committee will discuss a proposed addition to the Division of Anti-Infective Drug Products' antimicrobial points to consider clinical trials document. "This addition concerns guidance on the conduct and analysis of clinical trials of antimicrobial drug products in the treatment of sepsis and potential product labeling for products establishing effectiveness in the treatment of sepsis," a June 25 Federal Register notice states. In the afternoon of July 23, the committee will turn to a discussion of the use of quinolone-class antimicrobials as investigational drugs in children. Meetings will begin both days at 8:30 a.m. in conference rooms D and E.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth